Format

Send to

Choose Destination
J Inherit Metab Dis. 2010 Oct;33(Suppl 2):S273-81. doi: 10.1007/s10545-010-9103-9. Epub 2010 May 20.

Guidelines for implementation of population-based newborn screening for severe combined immunodeficiency.

Author information

1
New England Newborn Screening Program, UMass Medical School, Jamaica Plain, MA 02130, USA. anne.comeau@umassmed.edu

Abstract

Severe combined immunodeficiency (SCID) is a Primary Immune Deficiency that is under consideration for population-based newborn screening (NBS) by many NBS programs, and has recently been recommended for inclusion in the US uniform panel of newborn screening conditions. A marker of SCID, the T cell receptor excision circle (TREC), is detectable in the newborn dried blood spot using a unique molecular assay as a primary screen. The New England Newborn Screening Program developed and validated a multiplex TREC assay in which both the TREC analyte and an internal control are acquired from a single punch and run in the same reaction. Massachusetts then implemented a statewide pilot SCID NBS program. The authors describe the rationale for a pilot SCID NBS program, a comprehensive strategy for successful implementation, the screening test algorithm, the screening follow-up algorithm and preliminary experience based on statewide screening in the first year. The Massachusetts experience demonstrates that SCID NBS is a program that can be implemented on a population basis with reasonable rates of false positives.

PMID:
20490925
DOI:
10.1007/s10545-010-9103-9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center